<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01447758</url>
  </required_header>
  <id_info>
    <org_study_id>LEO 29102-C26</org_study_id>
    <nct_id>NCT01447758</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis. A Multicentre, Prospective, Randomised Phase Ib Study in Subjects Investigating Safety,Tolerability and Pharmacokinetics of LEO 29102 Cream (2.5 mg/g) When Treating Atopic Dermatitis Lesions Twice Daily for 7 Days (Cohorts I, II and III) and 6 Weeks (Cohort IV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase Ib study is to investigate the safety, tolerability and
      pharmacokinetics of LEO 29102 2,5 mg/g cream when treating atopic dermatitis (AD) lesions
      from 10 up to 100% of the body surface area (BSA) twice daily (BID) for 7 days (Cohorts I,
      II, III) and from 10% up to 50% of BSA (bid) for 6 weeks (Cohort IV). This trial will be
      performed in four cohorts. Cohort I, II and III includes patients with a larger BSA that
      increases from one cohort to the next. After each cohort (Cohort I, II)a blinded evaluation
      of the safety and tolerability data will assess whether a stepwise increase in the percentage
      of &quot;to be treated BSA&quot; is justified. Cohort IV will start dosing after finalisation of Cohort
      II and after submission of data from Cohort I and II to the national authority and IEC for
      review.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK profile - Cohort I, II, III</measure>
    <time_frame>Predose, 1h, 2h, 4h, 6h, 12h, 13h, 14h, 16h, 18h, 24h (on day 1 and 7) and 36h, 48h, 72h (on day 7 only)</time_frame>
    <description>Cmax, AUC, Tmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability and safety of LEO 29102 cream - Cohort I, II, III</measure>
    <time_frame>14 Days</time_frame>
    <description>Number of subjects with AEs and change from baseline in vital signs (blood pressure, pulse rate, respiratory rate body temperature), ECG parameters, clinical laboratory, physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK profile - Cohort IV</measure>
    <time_frame>Day 1, 14, 28, 42: Pre AM dose and 1h, 2h, 4h, 6h, 12h. Post AM dose, but prior to PM dose and 24 h, 36h, 48h, 72h after AM dose Day 42</time_frame>
    <description>Cmax, AUC, Tmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability and safety of LEO 29102 cream - Cohort IV</measure>
    <time_frame>49 Days</time_frame>
    <description>Number of subjects with AEs and change from baseline in vital signs (blood pressure, pulse rate, respiratory rate body temperature), ECG parameters, clinical laboratory, physical examination, SCORAD, EASI and IGA by stratum, treatment and visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dermis concentration of LEO 29102 and its metabolites LEO 28386 and LEO 26989 after multiple topical applications in subjects with AD (Cohorts II and IV, Subgroup 1)</measure>
    <time_frame>10 Days for cohort II; 42 days for cohort IV, subgroup 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers in AD lesions before and after multiple topical applications in subjects with AD (Cohorts I and IV, Subgroup 2)</measure>
    <time_frame>10 Days for cohort I, 42 days for cohort IV, subgroup 2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>LEO 29102 2,5 mg/g cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 29102 Cream Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 29102</intervention_name>
    <description>Cream, 1,7mg/cm2 BSA, BID, 7 days In Cohort I, II and III, 6 weeks in Cohort IV</description>
    <arm_group_label>LEO 29102 2,5 mg/g cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 29102 Cream Vehicle</intervention_name>
    <description>Cream, 1,7mg/cm2 BSA, BID, 7 days in Cohort I and II, 6 weeks in Cohort IV</description>
    <arm_group_label>LEO 29102 Cream Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis of AD defined according to Hanifin and Rajka.

          2. Investigator Global Assessment scored as mild (2) to severe (4) AD.

          3. At screening, AD lesions amenable for treatment involving 10% to &lt; 25% (Cohort I), 25%
             to &lt; 50% (Cohort II), 50% to 100% (Cohort III) and 10% to &lt; 50% (Cohort IV) of the
             total BSA.

          4. On Day -1, AD lesions amenable for treatment involving 10% to &lt; 28% (Cohort I), 25% to
             &lt; 55% (Cohort II), 50% to 100% (Cohort III) and 10% to &lt; 55% (Cohort IV) of the total
             BSA.

          5. Adult male or female subjects, aged 18 to 65 years, inclusive.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diamant Thaci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goethe University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Dermatologie und Allergologie der Universität Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätshautklinik Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, Johann Wolfgang Goethe-University</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera gGmbH</name>
      <address>
        <city>Gera</city>
        <zip>07584</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Center North</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30449</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätshautklinik Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2011</study_first_submitted>
  <study_first_submitted_qc>October 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2011</study_first_posted>
  <last_update_submitted>April 30, 2013</last_update_submitted>
  <last_update_submitted_qc>April 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

